Drug Profile
Granisetron oral solution - PediatRx
Alternative Names: GranisolLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PediatRx
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
Most Recent Events
- 25 Jan 2019 Seelos Therapeutics merged with Apricus Biosciences to form Seelos Therapeutics
- 18 Apr 2012 Granisetron oral solution - PediatRx is available for licensing as of 13 Mar 2012. http://www.apricusbio.com
- 28 Jan 2012 Apricus Biosciences acquires granisetron oral solution from PediatRx for non-US territories and receives copromotion rights within USA